VR Adviser’s Cullinan Oncology CGEM Stock Holding History

VR Adviser’s Portfolio CGEM Stock Details CGEM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$25.1M	Hold	1,379,965	–	–	0.76%	22
2026 Q1	$19.6M	Hold	1,379,965	–	–	0.73%	26
2025 Q4	$14.3M	Hold	1,379,965	–	–	0.71%	25
2025 Q3	$8.18M	Hold	1,379,965	–	–	0.46%	28
2025 Q2	$10.4M	Hold	1,379,965	–	–	0.78%	23
2025 Q1	$10.4M	Hold	1,379,965	–	–	0.89%	20
2024 Q4	$16.8M	Hold	1,379,965	–	–	1.15%	20
2024 Q3	$23.1M	Hold	1,379,965	–	–	1.21%	24
2024 Q2	$24.1M	Buy	+1,379,965	New	+$29.4M	1.53%	20
2021 Q4	–	Sell	-706,050	Closed	-$15.9M	–	28
2021 Q3	$15.9M	Sell	706,050 -270,095	-28%	-$7.22M	2.05%	17
2021 Q2	$25.1M	Sell	976,145 -200,000	-17%	-$6.15M	3.05%	12
2021 Q1	$49M	Buy	+1,176,145	New	+$47.7M	5.32%	6

Other funds holding CGEM

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

VR Adviser's CGEM Position: Q2 2026 in Review

VR Adviser held its Cullinan Oncology (CGEM) position steady in Q2 2026 at 1,379,965 shares worth $25.1M. The position accounts for 0.76% of the portfolio, ranked #22.

VR Adviser first reported a position in CGEM in Q1 2021 and has held it in 12 quarters since. The position peaked at $49M in Q1 2021. 184 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

VR Adviser held 1,379,965 shares of Cullinan Oncology worth $25.1M as of Q2 2026.
VR Adviser left its Cullinan Oncology share count unchanged in Q2 2026.
Cullinan Oncology made up 0.76% of VR Adviser's portfolio in Q2 2026, its #22 holding.
VR Adviser first reported a position in Cullinan Oncology in Q1 2021 and has held it in 12 quarters since.
VR Adviser's Cullinan Oncology position peaked at $49M in Q1 2021.
184 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on VR Adviser's 13F filing for Q2 2026, filed 14 Aug 2026.